The Fukangning Tablets segmentation by application delineates five primary therapeutic categories: cardiovascular (30%), metabolic (25%), respiratory (20%), central‑nervous‑system (CNS) (15%), and gastrointestinal (10%). The cardiovascular segment, encompassing antihypertensive and anti‑ischemic formulations, commands the largest share due to the high prevalence of hypertension and coronary disease in the target population, driving both volume sales and premium pricing. Metabolic applications, primarily antidiabetic and lipid‑modulating tablets, contribute a substantial 25% of revenue, reflecting rising incidence of metabolic syndrome and associated reimbursement incentives. Respiratory tablets, used for asthma and chronic obstructive pulmonary disease, account for 20% of the market, supported by expanding outpatient treatment protocols. The CNS segment, covering anxiolytic and antiepileptic tablets, supplies 15% of total sales, with growth tied to increased mental‑health awareness. Finally, gastrointestinal tablets, including antacid and pro‑kinetic agents, represent 10% of the market, sustaining a modest but stable demand base. These percentages are reflected in the accompanying pie‑chart, illustrating each application’s proportional impact on the overall Fukangning Tablets market size.
